Trials / Recruiting
RecruitingNCT07113522
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics With Multiple Therapies in Participants With Active Crohn's Disease or Active Ulcerative Colitis (ASCEND-IBD)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Mirador Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
Detailed description
The purpose of this platform study is to assess the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) to evaluate multiple oral or parenteral experimental therapies for moderately to severely active Crohn's Disease or Ulcerative Colitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-501 | MT-501 |
| DRUG | MT-201 | MT-201 |
Timeline
- Start date
- 2025-06-26
- Primary completion
- 2027-04-30
- Completion
- 2028-02-04
- First posted
- 2025-08-08
- Last updated
- 2026-03-12
Locations
66 sites across 5 countries: United States, Canada, Georgia, Moldova, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07113522. Inclusion in this directory is not an endorsement.